No 01 2018 – Coming soon

The exercise period for warrants of series TO1 in Isofol ended on 30 March 2026 and the outcome shows that a total of 37,301,067 TO1 were exercised for subscription of 37,301,067 new shares, corresponding to a subscription rate of approximately 93.57 per cent.

A new study from the University of Gothenburg may help guide the development of better influenza vaccines. 

A new COVID‑19 variant nicknamed Cicada (BA.3.2) is spreading internationally, with early data indicating notable immune escape but no clear evidence of more severe disease than current strains.

The new research hub in Cambridge, Massachusetts, in the greater Boston area, will serve as Zealand Pharma’s primary US address and is expected to be operational from September 2026.

Thor Medical has entered into a multiyear frame agreement with Node Pharma for the supply of radium-224 and lead-212 for preclinical use.

MSD and Terns Pharmaceuticals have entered into a definitive agreement under which MSD, through a subsidiary, will acquire Terns for an approximate equity value of USD 6.7 billion.

Nordic research shows that there were no negative risks associated with pregnant women receiving the COVID-19 vaccine during the pandemic.